Alvotech (ALVO)
NASDAQ:ALVO
Want to see ALVO full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.02Last Year’s EPS
0.03Same Quarter Last Year
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong pipeline momentum, rising EBITDA margins, meaningful commercial traction (notably AVT02 market share), a strategic Fujifilm manufacturing partnership and constructive full-year guidance are clear positives. Offsetting these are a material Q1 revenue decline (-20% YoY) and low product margin (11%) driven by deliberate manufacturing slowdowns to address regulatory findings, along with negative operating cash flow, a modest cash balance ($64M) and substantial quarterly interest payments. The company emphasizes derisking for stronger 2027 growth, but near-term financial and regulatory execution risks remain.Company Guidance
Pipeline and Regulatory Progress
Resubmissions of BLAs for biosimilars to Simponi, Eylea (high-dose and low-dose), Prolia and Xgeva are in the final stage of completion; EMA marketing authorization application submitted for AVT16 and AVT80 (Entyvio); AVT29 (high-dose Eylea) on track for EMA submission in 2026 and first patients enrolled in pivotal study supporting a 2028 U.S. submission.
Commercial Momentum and Market Share Gains
AVT02 (Humira biosimilar) became the fastest-growing Humira biosimilar in the U.S., achieving ~10% market share; commercial presence expanded to over 90 countries; newly approved products (AVT03, AVT05, AVT06) began contributing incremental revenues in Europe, U.K. and Japan.
Manufacturing Diversification Agreement
Signed strategic manufacturing agreement with Fujifilm Biotechnologies to diversify capacity and add U.S.-based supply; technology transfer initiated with product supply to the U.S. expected to begin in H2 2027, supporting future launches and supply resilience.
Adjusted EBITDA Improvement
Adjusted EBITDA was $24 million in Q1 2026, up from $21 million in Q1 2025 (≈+14%), with EBITDA margin improving to 23% from 15% a year earlier (an improvement of 8 percentage points).
Gross Margin Stability
Reported gross margin of 57% for Q1 2026, a modest improvement of 6 basis points versus the same period last year, reflecting a balanced mix of product and licensing revenues.
Full-Year Guidance and Longer-Term Growth Outlook
Full-year 2026 revenue guidance of $650–$700 million (targeting continued double-digit growth vs. 2025) and adjusted EBITDA guidance of $180–$220 million; company expects stronger manufacturing output and material margin improvement entering 2027.
ALVO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALVO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $3.57 | $3.20 | -10.36% |
Mar 18, 2026 | $3.80 | $3.58 | -5.79% |
Nov 12, 2025 | $5.60 | $5.52 | -1.43% |
Aug 13, 2025 | $8.96 | $8.47 | -5.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Alvotech (ALVO) report earnings?
Alvotech (ALVO) is schdueled to report earning on Aug 19, 2026, After Close (Confirmed).
What is Alvotech (ALVO) earnings time?
Alvotech (ALVO) earnings time is at Aug 19, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALVO EPS forecast?
ALVO EPS forecast for the fiscal quarter 2026 (Q2) is -0.02.